COGT
Cogent Biosciences, Inc. Common Stock
stockNASDAQ
unum therapeutics is a cambridge, massachusetts-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. unum was built to transform cancer treatment through the discovery, development and commercialization of novel antibody-coupled cellular immunotherapies. unum has built an antibody-coupled t-cell receptor (actr) platform that, when combined with tumor-specific antibodies, directs an individual's cytotoxic t-lymphocytes (ctls) to kill tumor cells. in contrast to other approaches that hit a single target and treat a narrow set of tumors, unum's approach is not restricted by antigens and may have applications for treating many types of cancers. unum's vision: a single cell therapy that can augment the activity of multiple antibodies to treat many different cancers. unum's lead program based on actr technology is currently in phase i clinical testing to assess safety and efficacy in certain forms of leukemia and lymphoma. in parallel, unum is act
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 31.86 | 2026-09-28 | -2.62% | -2.296 |
| 1M | 34.76 | 2026-09-04 | -10.74% | 1.153 |
| 3M | 39.44 | 2026-07-06 | -21.34% | 1.669 |
| 6M | 35.42 | 2026-04-06 | -12.41% | 1.332 |
| 1Y | 15.90 | 2025-10-06 | +95.13% | 2.428 |
| 2Y | 11.11 | 2024-10-04 | +179.25% | — |
| 5Y | 8.81 | 2021-10-05 | +252.16% | 1.211 |
Cogent Biosciences, Inc. Common Stock (NASDAQ:COGT) stock price today is $31.03, and today's volume is 1,172,135. COGT is down 1.789% today. The 30 day average volume is 1.90M. COGT market cap is $5.38B with 173.52M shares outstanding.